206-838-5110 ext. 102 general@etubics.com

SEATTLE (May 16, 2012) – Etubics Corporation, a bio-pharmaceutical company with a platform technology that delivers a long lasting “active” immune response against diseases, and Duke Cancer Institute will present a review of a collaborative first-in-man Phase I/II clinical trials for an immunotherapeutic treatment for late stage colorectal cancer patients at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. Dr. Michael Morse, associate professor of medical oncology at the Duke Cancer Institute and Principle Investigator for the clinical trial, will present from 8 a.m. to noon on Monday, June 4, 2012 at S Hall A2, Poster Board 7B. The title of the presentation is “Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA- expressing malignancies in a phase I/II clinical trial”.

Dr. Morse will present on Etubics therapeutic colorectal cancer immunotherapeutic program which has completed Phase I/II Clinical Trials led by Duke. The primary objective was to determine the safety of the immunotherapy with Ad5 [E1, E2B-]-CEA, trade name ETBX-011, in patients with advanced metastatic CEA-expressing cancer. The secondary objectives were to evaluate CEA-specific immune response to the treatments and obtain preliminary data on survival.

To date, Etubics has been very encouraged by the clinical outcome of ETBX-011 and no safety issues or adverse effects have been reported in human studies. Metastatic colorectal cancer patients treated in the trial with ETBX-011 currently have an average overall survival of 12 months.

“We are encouraged by the positive safety and overall survival data from the Phase I and II clinical trials for ETBX- 011. We plan to move to a pivotal Phase III trial by year end, pending FDA agreement” stated Dr. Morse.

Etubics is developing next generation vaccines and immunotherapy product candidates, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform. The Etubics Platform delivers a long lasting “active” immune response against diseases and induces Cell Mediated Immunity (CMI). The Company believes that its Platform enables the rapid expansion of its pipeline of immunotherapeutic drugs for a wide variety of cancers and vaccines for difficult to treat infectious diseases.

Etubics Phase I/II colorectal cancer trial has been funded primarily through grants and contracts from the National Cancer Institute (NCI) to the Company, including NCI Phase II SBIR Grant #2R44CA134063 and NCI Phase II SBIR Contract #HHSN261201100097C. The NCI also awarded earlier grants to Etubics for its colorectal and breast cancer pre-clinical and colorectal clinical work. The NCI has also given Etubics a $1.5 million contract to manufacture ETBX- 011 for the next clinical trial.

About Etubics

Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .

www.etubics.com

Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.

###

Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 ines@etubics.com

Click to Download PDF